Safety of Oral Propranolol for Infantile Hemangioma

OBJECTIVES: The safety of oral propranolol for infantile hemangioma has not yet been studied at population level since the pediatric use marketing authorization was obtained in Europe. METHODS: A survey of a nationwide, claim-based observational cohort of children International Classification of Diseases, 10th Revision . The main analysis was conducted separately on “healthy” children ( N = 1484), that is, free from of any prespecified underlying disease and on children with 1 of these underlying diseases ( N = 269). RESULTS: In all, 1753 patients CONCLUSIONS: In this study on a large continuous nationwide claims database, we confirm the safety profile of oral propranolol in healthy children to be good.